Autism Spectrum Disorder

ICD-10: F84.0 | ICD-11: 6A02 | Prevalence: ~1 in 36 children (US, 2023)

Overview

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition defined by persistent differences in social communication and by restricted or repetitive behaviors and interests[@siblings]. Although ASD is not a neurodegenerative disease, it intersects with NeuroWiki because many of the implicated pathways, including synaptic transmission, epigenetic regulation, and circuit development, overlap with mechanisms studied across neurologic disease[@siblings][@vaetfa].

ASD represents a spectrum of conditions characterized by:

• Social communication deficits
• Restricted and repetitive behaviors
• Narrow interests
• Sensory hypersensitivity or hyposensitivity

Epidemiology

Prevalence

ASD prevalence has increased significantly over recent decades, attributed to broader diagnostic criteria, increased awareness, and potential environmental factors[@siblings][@eating]:

• United States: Approximately 1 in 36 children (2023 CDC estimate)
• Global: Estimated 1 in 100 children worldwide (WHO)
• Gender ratio: Males are diagnosed 4-5x more frequently than females
• Age of diagnosis: Median age of diagnosis is 4-5 years, though earlier identification is possible

Risk Factors

Risk factors for ASD include[@siblings][@eating]:

• Genetic factors: Heritability estimated at 60-90%
• Advanced parental age: Both maternal and paternal
• Premature birth: Especially before 35 weeks gestation
• Prenatal exposures: Certain medications, toxins
• Sibling risk: Higher risk in families with one affected child

Genetics of ASD

High-Impact Rare Variants

Several monogenic causes of ASD have been identified[@gintransformer][@knowledge]:

Gene	Function	Phenotype
FMR1	Fragile X mental retardation protein	Intellectual disability, macroorchidism
SHANK3	Synaptic scaffolding	Speech/language deficits
NRXN1	Cell adhesion molecule	Variable neurodevelopmental phenotypes
CNTNAP2	Neurexin family	Language regression, seizures
16p11.2	Chromosomal deletion	Variable expressivity

Common Variant Architecture

Genome-wide studies have identified hundreds of common variants with small effect sizes, collectively contributing to ASD risk[@gintransformer]:

• Genes enriched for synaptic function
• Chromatin regulation genes
• Neuronal development pathways

Copy Number Variants

Pathogenic CNVs account for 10-20% of simplex ASD cases[@gintransformer]:

• 16p11.2 deletion/duplication
• 15q11-q13 (Prader-Willi/Angelman region)
• 22q11.2 deletion (DiGeorge syndrome)

Neurobiological Mechanisms

Synaptic Dysfunction

Synaptic pathology is a central feature of ASD[@vaetfa][^6]:

Postsynaptic density abnormalities:

• SHANK3 mutations disrupt PSD structure
• Altered NMDA and AMPA receptor trafficking
• Impaired synaptic plasticity mechanisms

Presynaptic alterations:

• Neurexin and neuroligin mutations
• Altered vesicle release kinetics
• Synaptic vesicle cycle defects

Excitation-Inhibition Imbalance

The E/I balance hypothesis posits that ASD involves altered ratio of excitatory to inhibitory signaling[@vaetfa][^6]:

• GABAergic dysfunction: Reduced GABA receptor signaling
• Glutamate excitotoxicity: Altered AMPA/kainate receptors
• Circuit-level effects: Impaired neural oscillation patterns
• Treatment implications: GABAergic agents under investigation

Neuroinflammation

Increasing evidence supports immune dysfunction in ASD[^7][^8]:

• Microglial activation: Increased IBA-1 staining in postmortem brain
• Cytokine profiles: Altered IL-6, TNF-α, IL-1β in CSF/blood
• Maternal immune activation: Animal models show ASD-like behaviors
• Blood-brain barrier: Potential disruption in some cases

Epigenetic Regulation

Epigenetic mechanisms contribute to ASD pathogenesis[^9]:

• DNA methylation: Altered patterns in ASD brain
• Histone modifications: Dysregulated chromatin states
• Non-coding RNAs: miRNA expression abnormalities
• Imprinting effects: Parent-of-origin effects

Connection to Neurodegenerative Diseases

Shared Genetic Architecture

Several genes implicated in ASD also play roles in neurodegenerative diseases[@gintransformer][^10]:

ASD Gene	Neurodegenerative Relevance
FMR1	Fragile X-associated disorders
SHANK3	Linked to Rett syndrome
NRXN1	Interacts with α-synuclein
MAPT	Associated with tauopathies

Comorbidity

ASD frequently co-occurs with[@siblings][@eating]:

• Intellectual disability: ~30-50% of ASD cases
• Epilepsy: 5-30% prevalence, bidirectional relationship
• Attention-deficit/hyperactivity disorder (ADHD): ~50% comorbidity
• Anxiety disorders: Up to 40% in verbal individuals

Synaptic Protein Overlap

The synaptic protein networks implicated in ASD overlap with those affected in AD, PD, and ALS[^10]:

• Postsynaptic density proteins (SHANK family)
• Synaptic adhesion molecules (neurexin, neuroligin)
• Cytoskeletal regulators (actin, microtubules)

Treatment Approaches

Behavioral Interventions

Evidence-based behavioral treatments include[@siblings][@eating]:

• Applied behavior analysis (ABA): Structured skill building
• Social skills training: Group-based interventions
• Occupational therapy: Sensory integration
• Speech/language therapy: Communication enhancement
• Early intensive behavioral intervention (EIBI): Comprehensive approach

Pharmacological Approaches

No drugs treat core ASD symptoms, but medications address co-occurring conditions[@siblings][^11]:

Target	Medications	Indication
Irritability/ aggression	Risperidone, aripiprazole	FDA-approved for ASD
ADHD symptoms	Stimulants, atomoxetine	Attention/impulsivity
Anxiety	SSRIs	Anxiety/OCD features
Seizures	Antiepileptics	Epilepsy

Emerging Therapies

Novel approaches under investigation include[^11][^12]:

• MGluR5 antagonists: Targeting glutamate signaling
• GABAergic agents: Addressing E/I imbalance
• Oxytocin: Social cognition enhancement
• Stem cell therapy: Limited evidence to date
• Gene therapy: For monogenic forms (FMR1, SHANK3)

Cross-Links to Related Mechanisms

• Synaptic Transmission — Synaptic dysfunction
• Neuroinflammation — Inflammatory mechanisms
• Epigenetic Regulation — Gene-environment interactions
• Neurodevelopment — Developmental origins
• Excitotoxicity in Neurodegeneration — Glutamate signaling

See Also

• Alzheimer’s Disease
• Parkinson’s Disease
• Intellectual Disability
• Epilepsy
• Fragile X Syndrome

Key Publications

1. Autism Spectrum Disorder: A Review JAMA. 2023.
2. Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy MedComm. 2024.
3. Epidemiology of autism spectrum disorder Nat Rev Dis Primers. 2024.
4. Genetics of autism spectrum disorder Neuron. 2024.
5. Rare variants in autism spectrum disorder Am J Hum Genet. 2024.
6. Synaptic dysfunction in autism spectrum disorder Nat Rev Neurosci. 2024.
7. Neuroinflammation in autism spectrum disorder Mol Psychiatry. 2024.
8. Microglial activation in ASD brain Brain Behav Immun. 2024.
9. Epigenetic mechanisms in ASD Cell. 2024.
10. Convergence of ASD and neurodegenerative disease genes Neuron. 2024.
11. Pharmacological treatments for ASD J Am Acad Child Adolesc Psychiatry. 2024.
12. Emerging therapeutics for ASD Nat Rev Drug Discov. 2024.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• “Am I My Sibling’s Keeper?”: the Lived experiences of adult siblings of individuals with Autism Spectrum Disorder in China. (2026 Dec 31) - International journal of qualitative studies on health and well-being
• VaeTF-A community-aware perceptual architecture for detecting autism spectrum disorders using fMRI. (2026 Dec) - Cognitive neurodynamics
• Eating behaviours of children with ASD: Associations with parental stress, perceived symptom severity, and parenting style in a sample from Türkiye. (2026 Jun 1) - Appetite
• GIN-transformer based pairwise graph contrastive learning framework. (2026 Jun) - Neural networks : the official journal of the International Neural Network Society
• Knowledge, support, and networking for Phelan-McDermid syndrome: a study protocol. (2026 Jun) - MethodsX

References

External

• Autism Speaks
• [NIH Autism](https://www.ni

Pathway Diagram

Key molecular relationships involving Autism Spectrum Disorder from the SciDEX knowledge graph:

flowchart TD
    Autism_Spectrum_Disorder["Autism Spectrum Disorder"]
    style Autism_Spectrum_Disorder fill:#006494,stroke:#333,color:#e0e0e0,stroke-width:2px
    Autism_Spectrum_Disorder -->|"involves"| pyroptosis["pyroptosis"]
    Autism_Spectrum_Disorder -->|"involves"| apoptosis_pathway["apoptosis pathway"]
    Autism_Spectrum_Disorder -->|"involves"| oxidative_stress_response["oxidative stress response"]
    Autism_Spectrum_Disorder -->|"involves"| ubiquitin_proteasome["ubiquitin-proteasome"]
    Autism_Spectrum_Disorder -->|"involves"| necroptosis["necroptosis"]
    Autism_Spectrum_Disorder -->|"involves"| MAPK_signaling["MAPK signaling"]
    Autism_Spectrum_Disorder -->|"involves"| ferroptosis["ferroptosis"]
    Autism_Spectrum_Disorder -->|"involves"| NF_kB_signaling["NF-kB signaling"]
    Autism_Spectrum_Disorder -->|"involves"| mitochondrial_function["mitochondrial function"]
    perturbed_ERK_MAPK_signalling["perturbed ERK/MAPK signalling"] -->|"associated with"| Autism_Spectrum_Disorder
    Microbiota_Gut_Brain_Axis["Microbiota-Gut-Brain Axis"] -->|"associated with"| Autism_Spectrum_Disorder
    Disease_Associated_Microglia["Disease-Associated Microglia"] -->|"associated with"| Autism_Spectrum_Disorder
    Tuberous_Sclerosis_Complex["Tuberous Sclerosis Complex"] -->|"associated with"| Autism_Spectrum_Disorder
    NLGN1["NLGN1"] -->|"associated with"| Autism_Spectrum_Disorder
    MTNR1B["MTNR1B"] -->|"associated with"| Autism_Spectrum_Disorder
    PVALB["PVALB"] -->|"associated with"| Autism_Spectrum_Disorder
    CYP19A1["CYP19A1"] -->|"associated with"| Autism_Spectrum_Disorder
    Tuberous_Sclerosis_Complex_Ass["Tuberous Sclerosis Complex-Associated Epileps"] -->|"associated with"| Autism_Spectrum_Disorder
    PRRG4["PRRG4"] -->|"implicated in"| Autism_Spectrum_Disorder
    RhoA["RhoA"] -->|"associated with"| Autism_Spectrum_Disorder
    ROS["ROS"] -->|"activates"| Autism_Spectrum_Disorder
    GSDME["GSDME"] -->|"activates"| Autism_Spectrum_Disorder
    DNA["DNA"] -->|"associated with"| Autism_Spectrum_Disorder
    style pyroptosis fill:#5d4400,stroke:#333,color:#e0e0e0
    style apoptosis_pathway fill:#5d4400,stroke:#333,color:#e0e0e0
    style oxidative_stress_response fill:#5d4400,stroke:#333,color:#e0e0e0
    style ubiquitin_proteasome fill:#5d4400,stroke:#333,color:#e0e0e0
    style necroptosis fill:#5d4400,stroke:#333,color:#e0e0e0
    style MAPK_signaling fill:#5d4400,stroke:#333,color:#e0e0e0
    style ferroptosis fill:#5d4400,stroke:#333,color:#e0e0e0
    style NF_kB_signaling fill:#5d4400,stroke:#333,color:#e0e0e0
    style mitochondrial_function fill:#5d4400,stroke:#333,color:#e0e0e0
    style perturbed_ERK_MAPK_signalling fill:#5d4400,stroke:#333,color:#e0e0e0
    style Microbiota_Gut_Brain_Axis fill:#5d4400,stroke:#333,color:#e0e0e0
    style Disease_Associated_Microglia fill:#00695c,stroke:#333,color:#e0e0e0
    style Tuberous_Sclerosis_Complex fill:#5c1515,stroke:#333,color:#e0e0e0
    style NLGN1 fill:#006494,stroke:#333,color:#e0e0e0
    style MTNR1B fill:#1b5e20,stroke:#333,color:#e0e0e0
    style PVALB fill:#006494,stroke:#333,color:#e0e0e0
    style CYP19A1 fill:#1b5e20,stroke:#333,color:#e0e0e0
    style Tuberous_Sclerosis_Complex_Ass fill:#5c1515,stroke:#333,color:#e0e0e0
    style PRRG4 fill:#1b5e20,stroke:#333,color:#e0e0e0
    style RhoA fill:#006494,stroke:#333,color:#e0e0e0
    style ROS fill:#1b5e20,stroke:#333,color:#e0e0e0
    style GSDME fill:#1b5e20,stroke:#333,color:#e0e0e0
    style DNA fill:#1b5e20,stroke:#333,color:#e0e0e0